Update Breast Cancer 2017 - Implementation of Novel Therapies

Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Ettl J, Huober JB, Lueftner D, Wallwiener M, Mueller V, Beckmann M, Belleville E, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Fasching P (2017)

Publication Type: Journal article

Publication year: 2017

Journal

Geburtshilfe und Frauenheilkunde Georg Thieme Verlag

Book Volume: 77

Pages Range: 1281-1290

Journal Issue: 12

DOI: 10.1055/s-0043-122885

Abstract

In recent years, numerous new therapy options for patients with breast cancer have been developed in clinical studies, with some options already approved for routine treatment. As the speed at which innovations are introduced increases, the importance of conferences also increases, as conferences are where the data underpinning new therapies are usually presented for the first time. This review looks at publications of the ASCO (American Society of Clinical Oncology) and ESMO (European Society of Medical Oncology) conferences in 2017, summarizes them and evaluates them in the context of existing data. The focus is on new insights for neoadjuvant therapy and new treatment options in the metastatic setting, such as the use of CDK4/6 inhibitors or PARP inhibitors. The first results of treatments with checkpoint inhibitors are presented. With the patent expiry of trastuzumab, a number of study results for trastuzumab biosimilars have also been published. The digitization of patient care provides the first results on quality of life and prognosis of patients with advanced cancer. Digital communications between patients and physicians are being evaluated in several studies in Germany. As the discussion about patient-relevant endpoints for patients in the metastatic setting continues, overall survival rates from studies of big endocrine-based therapies are urgently needed. Preliminary analyses of small study cohorts offer initial insights. In the context of improving patient care, in the coming years, questions will center on which patients particularly benefit from certain therapies and which patients need particular protection from specific side effects. Questions about these predictors are raised in many scientific projects as attention increasingly focuses on this topic.

Authors with CRIS profile

Naiba Nabieva Department of Obstetrics and Gynaecology Matthias Beckmann Lehrstuhl für Geburtshilfe und Frauenheilkunde Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Universitätsklinikum Ulm DE Germany (DE) Eberhard Karls Universität Tübingen DE Germany (DE) Oncologianova GmbH DE Germany (DE) Marienhospital Bottrop DE Germany (DE) Krankenhaus Nordwest DE Germany (DE) Centrum für Hämatologie und Onkologie Bethanien DE Germany (DE) Technische Universität München (TUM) DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Ruprecht-Karls-Universität Heidelberg DE Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) ClinSol GmbH & Co.KG DE Germany (DE) Universitätsklinikum Düsseldorf DE Germany (DE)

How to cite

APA:

Lux, M.P., Janni, W., Hartkopf, A.D., Nabieva, N., Taran, F.-A., Overkamp, F.,... Fasching, P. (2017). Update Breast Cancer 2017 - Implementation of Novel Therapies. Geburtshilfe und Frauenheilkunde, 77(12), 1281-1290. https://doi.org/10.1055/s-0043-122885

MLA:

Lux, Michael P., et al. "Update Breast Cancer 2017 - Implementation of Novel Therapies." Geburtshilfe und Frauenheilkunde 77.12 (2017): 1281-1290.

BibTeX: Download